News | October 24, 2007

Isosmolar Contrast Causes Less CIN

October 25, 2007 - Study results presented at TCT 2007 demonstrated that the use of the isosmolar contrast medium Visipaque (iodixanol), a nonionic isosmolar contrast medium used for X-ray images of soft tissues, primarily blood vessels and organs, resulted in a statistically significantly lower rate of contrast-induced nephropathy (CIN) than the low osmolar nonionic contrast agent ioversol.
Visipaque is reportedly the only contrast medium available for intravascular use that is isosmolar at all iodine concentrations. The study was conducted in 250 patients with diabetes who underwent either coronary angiography to determine if there was disease in the arteries or percutaneous coronary intervention to improve circulation of diseased arteries that supply blood to the heart muscle. The authors reported the use of the isosmolar contrast medium Visipaque resulted in a statistically significantly lower rate of CIN at 72 hours following contrast medium administration when compared with the low osmolar nonionic contrast agent ioversol (2.5 percent vs 8.3 percent; p = 0.047). Study investigators also noted that in the group of patients at highest risk, those who underwent a percutaneous coronary intervention procedure and received higher amounts of a contrast medium, Visipaque use also resulted in significantly lower rate of CIN at 72 hours than ioversol (2 percent vs 13.5 percent; p = 0.02).
“The incidence of CIN in high-risk patients is elevated and of clinical concern to physicians,” said Felipe Hernandez, M.D., interventional cardiologist, Hospital 12 de Octubre, Madrid. “Our study shows a low incidence of CIN with Visipaque in patients with diabetes after coronary angiography or angioplasty.”
Don Black, head for Research and Development at GE Healthcare said, “The results of the study reported by Dr. Hernandez provide additional insight for Isosmolar Visipaque and its effect on renal function. Contrast-induced nephropathy remains a very important clinical issue for physicians and patients. These results further add to research demonstrating that Visipaque has a low incidence of CIN in high-risk patients.”

For more information: www.gehealthcare.com

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media| January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media| July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media| June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media| March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media| January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media| October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init